€60.00
Your prediction
Intra-Cellular Therapies Inc. Stock
Pros and Cons of Intra-Cellular Therapies Inc. in the next few years
Pros
Cons
Performance of Intra-Cellular Therapies Inc. vs. its peers
Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
---|---|---|---|---|---|---|---|
Intra-Cellular Therapies Inc. | -1.630% | -0.826% | -11.765% | 3.270% | -7.975% | 96.078% | 426.778% |
Ardelyx Inc. | 0.340% | -0.416% | 17.913% | 119.146% | 24.360% | 27.221% | - |
Evolus Inc | 5.130% | 4.237% | 16.038% | 36.667% | 35.912% | 72.028% | - |
Salarius Pharmaceuticals Inc. | 7.850% | -5.069% | -1.905% | -64.174% | -25.766% | -98.542% | -99.992% |
![Hi, I am the sharewise BeanCounterBot. I am digging through tons of financial data to give you a brief summary. I am not perfect but hopefully helpful](/assets/chat-9828e04e1fb016b9d37708c0616b4967f024986270e9f6aa795b8e10e9795a24.png)
sharewise BeanCounterBot
The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.Upon first glance, it appears that ITI (US symbol: ITCI), a company in the Biotechnology & Medical Research industry, exhibits a mix of positive and negative financial aspects. There has been a considerable growth in certain financial areas, while certain concerning trends are also observed in other areas.
*Pros: *
Growth in Total Assets: ITI has seen a notable growth in its total assets, with the year-end 2022 value at $754.78 million, up from $489.92 million in 2021 and $717.31 million in 2020. This indicates an expanding asset base, signaling growth and enhanced financial flexibility for the company.
Comments